Market Closed -
Other stock markets
|
Pre-market 02:02:32 | |||
100.7 EUR | +0.40% | 100.4 | -0.25% |
04-24 | CARL ZEISS MEDITEC AG : Gets a Buy rating from UBS | ZD |
04-23 | CARL ZEISS MEDITEC AG : Receives a Sell rating from JP Morgan | ZD |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Sales forecast by analysts have been recently revised upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 34.47 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 4.21 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.88% | 9.65B | B+ | ||
+8.69% | 220B | B | ||
+6.69% | 183B | B- | ||
+10.90% | 133B | B- | ||
+25.41% | 107B | A- | ||
+0.27% | 63.05B | A- | ||
+12.72% | 51.74B | B+ | ||
+3.96% | 50.47B | B+ | ||
+0.40% | 40.91B | A | ||
+15.03% | 40.59B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AFX Stock
- Ratings Carl Zeiss Meditec AG